Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 October 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

High mortality with refractory ascites and Hep C recurrence

Mortality rates were higher following refractory ascites development while it was ongoing, and survival was poorer among patients having bacterial peritonitis or Hep C virus recurrence, finds January's American Journal of Transplantation.

News image

fiogf49gjkf04

Dr Nishidaa and colleagues retrospectively studied 1058 liver transplant recipients.

The researchers determined the incidence, etiology, timing, clinical features and treatment of refractory ascites.

The team also assessed risk factors for refractory ascites development, and predictors of refractory ascites disappearance.

In addition, the researchers evaluated predictors of survival following refractory ascites, and the impact of refractory ascites on patient survival.

The team noted that 62 patients developed refractory ascites, and its disappearance occurred in 27 of these 62 cases.

Patients having Hepatitis C virus had a significantly higher hazard rate of developing refractory ascites.

The team found no other baseline characteristic associated with refractory ascites.

Mortality rates were nearly 9 higher following refractory ascites development
American Journal of Transplantation

Cox stepwise regression analysis of the hazard rate of refractory ascites disappearance found 2 significant factors.

Using this analysis, Hepatitis C virus recurrence as the reason for developing refractory ascites was shown to result in a poorer outcome.

The researchers observed that an unknown reason for developing refractory ascites implied a favorable outcome.

Survival following refractory ascites was significantly poorer among patients having bacterial peritonitis or Hepatitis C virus recurrence.

Finally, the team noted that the mortality rate was nearly 9 higher in patients following refractory ascites development while it was ongoing.

However, the researchers found that if the refractory ascites disappeared, then the additional risk of death also disappeared.

Dr Nishidaa's team concluded, “This study illustrates the importance of developing an optimal treatment strategy.”

“Such a treatment strategy should effectively treat refractory ascites if it develops and also prevent Hepatitis C recurrence.”

Am J Transpl 2006: 6(1): 140
09 January 2006

Go to top of page Email this page Email this page to a colleague

 24 October 2017 
Predicting recurrence after curative rectal cancer surgery
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 23 October 2017 
Irradiated rectal cancer and chemoradiotherapy
 20 October 2017 
Hospital readmissions reduction program
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 20 October 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Surgical anastomosis at 1-year colorectal cancer surveillance
 19 October 2017 
Current management of chylous ascites
 18 October 2017 
NAFLD-related HCC in patients undergoing liver resection
 18 October 2017 
Hep E seroprevalence and hemodialysis
 18 October 2017 
Prebiotic and changes in the human gut microbiota
 17 October 2017 
Laparoscopic surgery use in Medicare patients with colon cancer
 17 October 2017 
Medication nonadherence and health care costs
 17 October 2017 
Asthma and IBD development
 16 October 2017 
Colorectal cancer screening and postpolypectomy surveillance colonoscopy
 16 October 2017 
Continuity of care after colorectal surgery
 16 October 2017 
Breastfeeding and the risk of IBD
 13 October 2017 
Treating patients with HCV and severe renal impairment
 13 October 2017 
Blood pressure management during abdominal surgery
 13 October 2017 
Food elimination diets for eosinophilic esophagitis
 12 October 2017 
Global recurrence of H. pylori
 12 October 2017 
Colonoscopy in an organized colorectal cancer screening program 
 12 October 2017 
Predicting advanced fibrosis in chronic hepatitis B
 11 October 2017 
Fecal microbiota transplantation for ulcerative colitis
 11 October 2017 
Sexual functioning in Hep C
 11 October 2017 
Ulcerative proctitis in pediatric-onset UC
 10 October 2017 
Quality standards in upper gastrointestinal endoscopy
 10 October 2017 
Eosinophilic esophagitis and swallowed topical corticosteroids
 10 October 2017 
Follow-up of positive results on fecal blood tests
 09 October 2017 
Diverticulitis and emergency department burden
 09 October 2017 
Global recurrence rate of H. pylori
 09 October 2017 
Clostridium difficile infection after ileostomy reversal
 06 October 2017 
Predicting nontreatment for Hep C
 06 October 2017 
Cow's milk–based formula and development of celiac disease
 06 October 2017 
Propofol for outpatient colonoscopy
 05 October 2017 
Pediatric candidates on the transplant wait list
 05 October 2017 
Incidence of sepsis in the USA
 05 October 2017 
Quality of life after chemoradiation in rectal cancer
 04 October 2017 
Clinical practice guidelines in colon cancer
 04 October 2017 
Peptic ulcer disease diagnosed in acute upper endoscopy
 04 October 2017 
Rural residence and risk of IBD
 03 October 2017 
Novel candidate risk genes for IBD
 03 October 2017 
Antibody tests and detecting celiac disease
 03 October 2017 
Environmental factors and IBD
 02 October 2017 
Full publication of Gastroenerology abstracts
 02 October 2017 
Interferon-free therapy in advanced liver disease
 02 October 2017 
Burden of NAFLD with advanced fibrosis in the USA
 29 September 2017 
Inpatient Gastroenterology training experience
 29 September 2017 
Proteomic analysis of IBD
 28 September 2017 
Social networking-based discussion group by ERCP doctors
 28 September 2017 
Incidence of biopsy-verified celiac disease
 27 September 2017 
Function of trypsin-3 in IBS
 27 September 2017 
Predictors of nonadherence in IBD
 27 September 2017 
Hep C treatment in the era of direct-acting anti-viral agents
 26 September 2017 
Chronic pancreatitis and pancreatic cancer risk
 26 September 2017 
Factors associated with the risk of metachronous gastric neoplasm
 26 September 2017 
Treatment of hyperactive delirium in advanced cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us